Emergent BioSolutions (NYSE:EBS) Announces Quarterly Earnings Results

Emergent BioSolutions (NYSE:EBS) announced its quarterly earnings results on Monday. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.40, Zacks reports. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%.

Emergent BioSolutions Trading Down 8.4 %

NYSE:EBS traded down $0.63 on Monday, reaching $6.85. The stock had a trading volume of 1,524,236 shares, compared to its average volume of 2,664,717. Emergent BioSolutions has a 12-month low of $1.82 and a 12-month high of $15.10. The company has a market cap of $371.16 million, a price-to-earnings ratio of -1.67 and a beta of 1.62. The firm’s fifty day moving average is $9.54 and its two-hundred day moving average is $9.09. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Wall Street Analyst Weigh In

Several research firms have weighed in on EBS. StockNews.com upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Monday, February 17th. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. Finally, Benchmark upped their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.